Defining Tumor & Immune Markers to Stratify Patients at Risk of Developing Multiple Myeloma from MGUS & Smoldering Myeloma
Time: 3:30 pm
day: Conference Day 1
Details:
- It is feasible of developing biomarkers from liquid biopsies in ALL and AML as evidenced from 2 projects in hematologic conditions
- MRD can be used as a prognostic indicator. Efforts are underway to develop biomarkers for progression from MGUS to Multiple Myeloma
- Inclusion of patient advocacy groups and patients with lived experience provides valuable insight into patient needs and needed data to improve patient outcomes
Hematology
